临床淋巴结阳性乳腺癌腋窝手术降阶梯的肿瘤学结局
NEOSENTITURK MF-1803前瞻性队列研究纳入976例cT1-4N1-3M0乳腺癌患者,在新辅助化疗后仅行前哨淋巴结活检(SLNB)或靶向腋窝清扫(TAD)。中位随访39个月,TAD与SLNB的腋窝复发率(0.3% vs 0.3%)和局部区域复发率(0.6% vs 1.1%)均无显著差异,总体局部区域复发率为0.9%。
要点
- 新辅助化疗后cN阳性转阴患者仅行TAD或SLNB的腋窝复发率极低(0.3%),局部区域复发率0.9%。
- TAD与SLNB在腋窝和局部区域复发率上无显著差异,无病生存率差异未达统计学意义。
- cN2-3分期和非 Luminal 型肿瘤与较差的5年疾病特异生存相关。
核心结论
- 在新辅助化疗后cN转阴的选定患者中,仅行TAD或SLNB后区域淋巴结放疗的短期腋窝和局部区域复发率极低。
- TAD相比SLNB是否带来明确生存优势尚需更长期随访研究证实。
研究设计与样本
- NEOSENTITURK MF-1803前瞻性队列注册试验,纳入37个中心976例cT1-4N1-3M0乳腺癌患者。
- 患者在新辅助化疗后接受SLNB(n=620)或TAD(n=356) alone,中位年龄46岁(范围21-80岁)。
- 主要结局为腋窝、局部区域或远处复发率、无病生存和疾病特异生存。
主要发现
- 局部区域复发率无显著差异(0.6%[2/356] vs 1.1%[7/620],P=0.50),总体局部区域复发率0.9%(9/976)。
关键数值与推荐
- 初始临床肿瘤分期、病理完全缓解和单独使用蓝染料作为示踪方法均与结局无关。
临床怎么用
- 对于新辅助化疗后cN转阴的选定乳腺癌患者,可考虑仅行TAD或SLNB替代腋窝淋巴结清扫。
- 术后应结合区域淋巴结放疗以维持低复发率。
- cN2-3分期和非Luminal型肿瘤患者需更密切随访。
局限性
- 短期随访结果(中位39个月),TAD与SLNB的生存差异需更长期研究证实。
- 研究为前瞻性队列注册,非随机对照设计。
- 结果仅适用于新辅助化疗后cN转阴的选定患者群体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Increasing evidence supports the oncologic safety of de-escalating axillary surgery for patients with breast cancer after neoadjuvant chemotherapy (NAC). OBJECTIVE: To evaluate the oncologic outcomes of de-escalating axillary surgery among patients with clinically node (cN)-positive breast cancer and patients whose disease became cN negative after NAC (ycN negative). DESIGN, SETTING, AND PARTICIPANTS: In the NEOSENTITURK MF-1803 prospective cohort registry trial, patients from 37 centers with cT1-4N1-3M0 disease treated with sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) alone or with ypN-negative or ypN-positive disease after NAC were recruited between February 15, 2019, and January 1, 2023, and evaluated. EXPOSURE: Treatment with SLNB or TAD after NAC. MAIN OUTCOMES AND MEASURES: The primary aim of the study was axillary, locoregional, or distant recurrence rates; disease-free survival; and disease-specific survival. Number of axillary lymph nodes removed was also evaluated. RESULTS: A total of 976 patients (median age, 46 years [range, 21-80 years]) with cT1-4N1-3M0 disease underwent SLNB (n = 620) or TAD alone (n = 356). Most of the cohort had a mapping procedure with blue dye alone (645 [66.1%]) with (n = 177) or without (n = 468) TAD. Overall, no difference was found between patients treated with TAD and patients treated with SLNB in the median number of total lymph nodes removed (TAD, 4 [3-6] vs SLNB, 4 [3-6]; P = .09). Among patients with ypN-positive disease, those who underwent TAD were more likely to have a lower median lymph node ratio (TAD, 0.28 [IQR, 0.20-0.40] vs SLNB, 0.33 [IQR, 0.20-0.50]; P = .03). At a median follow-up of 39 months (IQR, 29-48 months), no significant difference was found in the rates of ipsilateral axillary recurrence (0.3% [1 of 356] vs 0.3% [2 of 620]; P ≥ .99) or locoregional recurrence (0.6% [2 of 356] vs 1.1% [7 of 620]; P = .50) between the TAD and SLNB groups, with an overall locoregional recurrence rate of 0.9% (9 of 976). The initial clinical tumor stage, pathologic complete response, and use of blue dye alone as a mapping procedure were not associated with the outcome. Even though patients with TAD demonstrated an increased disease-free survival rate compared with the SLNB group, this difference did not reach statistical significance (94.9% vs 92.6%; P = .07). Factors associated with decreased 5-year disease-specific survival were cN2-3 axillary stage (cN1, 98.7% vs cN2-3, 96.8%; P = .03) and nonluminal type tumor pathologic characteristics (luminal, 98.9% vs nonluminal, 96.9%; P = .007). CONCLUSIONS AND RELEVANCE: The short-term results suggest very low rates of axillary and locoregional recurrence in a select group of patients with cN-negative disease after NAC treated with TAD alone or SLNB alone followed by regional nodal irradiation regardless of the SLNB technique or nodal pathology. Whether TAD might provide a clear survival advantage compared with SLNB remains to be proven in studies with longer follow-up.
引用
- Cabioglu N, Koçer HB, Karanlik H, et al. De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer. JAMA Surg. 2025. PMID: 39745737. doi:10.1001/jamasurg.2024.5913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。